MaxCyte, Inc. (MXCT) News

MaxCyte, Inc. (MXCT): $4.73

-0.09 (-1.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MXCT News Items

MXCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MXCT News Highlights

  • For MXCT, its 30 day story count is now at 6.
  • Over the past 23 days, the trend for MXCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about MXCT are MD, BIO and MA.

Latest MXCT News From Around the Web

Below are the latest news stories about Maxcyte Inc that investors may wish to consider to help them evaluate MXCT as an investment opportunity.

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22nd, 2022. Company ma

Yahoo | February 24, 2022

MaxCyte (MXCT) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares o

Yahoo | February 11, 2022

MaxCyte signs strategic platform license to advance tumor infiltrating lymphocyte programs

MaxCyte (MXCT) signed a strategic platform license ((SPL)) with Intima Bioscience, a biotech developing genetically engineered cell therapies for solid tumor cancer.Under the terms of

Seeking Alpha | February 1, 2022

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidatesNEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company develop

Yahoo | February 1, 2022

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 millionInstalled base of greater than 500 instruments 15 SPLs, covering more than 95 programs, of which over 15% have entered the clinicPrecommercial milestone revenue potential from our SPL programs exceeds $1.25 billion GAITHERSBURG, Md., Jan. 23, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focuse

Yahoo | January 24, 2022

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 14, 2022

Royce Value Trust, Inc. Buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Sells EQT Corp, ...

Investment company Royce Value Trust, Inc. (Current Portfolio) buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Eagle Materials Inc, Scientific Games Corp, sells EQT Corp, SmileDirectClub Inc, , Hilton Grand Vacations Inc, Kulicke & Soffa Industries Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Royce Value Trust, Inc..

Yahoo | December 17, 2021

Royce Global Value Trust, Inc. Buys Rogers Corp, Element Solutions Inc, Imax Corp

Investment company Royce Global Value Trust, Inc. (Current Portfolio) buys Rogers Corp, Element Solutions Inc, Imax Corp, TravelSky Technology, Haemonetics Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Royce Global Value Trust, Inc..

Yahoo | December 17, 2021

MaxCyte Inc. (NASDAQ: MXCT): The Most Interesting Shares Of The Day

In the last trading session, 1.06 million MaxCyte Inc. (NASDAQ:MXCT) shares changed hands as the company’s beta touched 0. With the company’s per share price at $10.02 changed hands at -$0.44 or -4.21% during last session. MXCT’s last price was a discount, traded about -74.05% off its 52-week high of $17.44. The share price had … MaxCyte Inc. (NASDAQ: MXCT): The Most Interesting Shares Of The Day Read More »

Marketing Sentinel | December 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3628 seconds.